Journal
JOURNAL OF ANTIBIOTICS
Volume 61, Issue 1, Pages 7-10Publisher
JAPAN ANTIBIOTICS RESEARCH ASSOC
DOI: 10.1038/ja.2008.102
Keywords
cyslabdan; imipenem potentiator; methicillin-resistant; Staphylococcus aureus; MRSA; Streptomyces sp K04-0144; beta-lactam
Ask authors/readers for more resources
Cyslabdan produced by Streptomyces sp. K04-0144 was found to potentiate imipenem activity against methicillin-resistant Staphylococcus aureus (MRSA). The MIC value of imipenem against MRSA was reduced from 16 to 0.0 15 mu g/ml in combination with cyslabdan. Study on anti-MRSA activity of other typical antibiotics in combination with cyslabdan showed that the potentiating activity was limited to beta-lactam antibiotics. Furthermore, among beta-lactam antibiotics, the activity of carbapenems was most remarkably poteintiated by cyslabdan.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available